Search results
Results from the WOW.Com Content Network
With the conjugate vaccine about 10% of babies develop redness at the site of injection, fever, or change in sleep. [1] Severe allergies are very rare. [1] Whole-cell vaccinations were developed alongside characterisation of the subtypes of pneumococcus from the early 1900s. [5] The first polysaccharide vaccine (tetravalent) was developed in ...
Pneumococcal pneumonia is a type of bacterial pneumonia that is caused by Streptococcus pneumoniae (pneumococcus). [1] It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal ...
In the U.S., all vaccines routinely recommended for children 6 years of age and younger are available in formulations that do not contain thimerosal. Two vaccines (a TD and the single-dose version of the trivalent influenza vaccine Fluvirin) may contain a trace of thiomersal from steps in manufacture, but less than 1 microgram of mercury per ...
Doctors have long urged people ages 50 and older to get a shot to protect against bacterial pneumonia. The Centers for Disease Control and Prevention now agrees.
These diseases include pneumonia, ear infections, sinus infections, meningitis and blood infections, and older people (and children under 2) are at the greatest risk. ... RSV, Cleveland Clinic ...
Concerns about thiomersal and vaccines are commonly expressed by anti-vaccine activists. Claims relating to the safety of thiomersal, a mercury-based preservative used in vaccines, are refuted, but still subject to fearmongering, notably claims it could cause neurological disorders such as autism, leading to its removal from most vaccines in the US childhood schedule. [1]
Adults over 65 should get one of the new RSV vaccines, CDC advisors decided. The CDC director must still recommend the shots before doses can be administered.
The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).